1065266-64-9

Basic information

• Product Name: 9-(4-acetylphenyl)-5-tert-butyl-8-(2-chlorophenyl)pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidin-3(2H)-one
• Synonyms: 9-(4-acetylphenyl)-5-tert-butyl-8-(2-chlorophenyl)pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidin-3(2H)-one
• CAS NO: 1065266-64-9
• Molecular Weight: 471.946
• Mol File: 1065266-64-9.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 9-(4-acetylphenyl)-5-tert-butyl-8-(2-chlorophenyl)pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidin-3(2H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 9-(4-acetylphenyl)-5-tert-butyl-8-(2-chlorophenyl)pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidin-3(2H)-one(1065266-64-9)
• EPA Substance Registry System: 9-(4-acetylphenyl)-5-tert-butyl-8-(2-chlorophenyl)pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidin-3(2H)-one(1065266-64-9)

Safety Data

• Hazardous Substances Data: 1065266-64-9(Hazardous Substances Data)

Upstream product

• 1065267-53-9 6-bromo-2-tert-butyl-7-(2-chlorophenyl)-4-hydrazino-8,8a-dihydropyrido[2,3-d]pyrimidine 
• 1065267-48-2 6-bromo-2-tert-butyl-4-chloro-7-(2-chlorophenyl)-8,8a-dihydropyrido[2,3-d]pyrimidine 
• 1065267-44-8 6-bromo-2-tert-butyl-7-(2-chlorophenyl)-8,8a-dihydropyrido[2,3-d]pyrimidin-4(3H)-one 
• 1065267-41-5 6-bromo-2-tert-butyl-7-(2-chlorophenyl)-8,8a-dihydropyrido[2,3-d]pyrimidin-4-amine 
• 1160912-87-7 C₁₂H₅BrCl₂N₂ 
• 1065267-37-9 5-bromo-6-(2-chlorophenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile 
• 75175-78-9 1-(2-chlorophenyl)-3-(dimethylamino)prop-2-en-1-one 
• 2142-68-9 1-(2-chlorophenyl)ethanone 
• 147283-46-3 6-(2-chlorophenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile 
• 1065267-31-3 9-bromo-5-tert-butyl-8-(2-chlorophenyl)pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidin-3(2H)-one 
• 149104-90-5 4-acetylphenylboronic acid 

Relevant articles and documents

Pyridopyrimidine based cannabinoid-1 receptor inverse agonists: Synthesis and biological evaluation

The synthesis, SAR and binding affinities are described for cannabinoid-1 receptor (CB1R) specific inverse agonists based on pyridopyrimidine and heterotricyclic scaffolds. Food intake and pharmacokinetic evaluation of several of these compounds indicate